# Oak Hill Bio Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oak-hill-bio-holdings

- Industry: Biotechnology
- Headquarters: Altrincham, UK
- Website: www.oakhillbioholdings.com
- Total disclosed funding: $33M
- Latest round: Series A (Jun 1, 2026)
- Investors on record: 4

## About

Based in the UK, Oak Hill Bio Holdings Ltd. specializes in the acquisition and development of late-stage therapeutics for rare diseases, particularly those overlooked by larger pharmaceutical firms.Founded in 2021, Oak Hill Bio Holdings Ltd. operates out of Altrincham, UK. The company focuses on developing therapies for rare diseases, specifically targeting treatments that have been deprioritized by larger firms. The company's funding history includes a recent Series A funding round where they raised USD 32.5 mn from investors including Balyasny Asset Management and Janus Henderson Investors. The total amount raised by the company so far is USD 32.5 mn, with their most recent deal completed on June 1, 2026.Oak Hill Bio Holdings specializes in the acquisition and development of late-stage rare disease therapeutics that have been deprioritized by larger pharmaceutical companies. Their primary product offerings include rugonersen (OHB-724), an antisense oligonucleotide designed to target Angelman syndrome, and mecasermin rinfabate (OHB-607), a recombinant human IGF-1/IGFBP-3 therapy aimed at addressing complications related to extremely premature birth. These products primarily serve the pediatric population afflicted by these rare conditions, providing crucial therapeutic interventions where limited options currently exist. The company operates primarily in North America, Europe, and select regions in Asia, focusing on markets with significant unmet medical needs for rare diseases.The revenue model for Oak Hill Bio Holdings is predicated on partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies, facilitating the development and commercialization of its therapeutic candidates. Transactions generally involve structured agreements where the company may receive upfront payments, milestone payments tied to development progress, and royalties on future sales. The firm’s flagship products, rugonersen and mecasermin rinfabate, are central to these revenue-generating activities, with their success in clinical trials potentially leading to lucrative licensing deals or sales agreements. By leveraging its innovative pipeline and strategic partnerships, Oak Hill Bio is positioned to engage in significant transactions as its products advance through clinical stages and approach market introduction.In June 2026, Oak Hill Bio Holdings Ltd. raised USD 32.5 mn in Series A funding, which will be utilized for operations and development activities. The company aims to expand its portfolio by launching new products that address rare diseases, with specific timelines for product rollouts yet to be disclosed. Additionally, Oak Hill Bio plans to broaden its market presence into new geographic regions, focusing on areas with high unmet medical need. This strategic approach is designed to maximize the therapeutic impact of its current offerings and enhance the overall market reach of the company.

## Funding rounds

- Series A, Jun 1, 2026, $33M — Balyasny Asset Management, VenBio, Janus Henderson Investors, Kuahiwi Management

## Investors

- Balyasny Asset Management — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A
- Janus Henderson Investors — Series A
- Kuahiwi Management — Series A